NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT07407283 2026-02-12
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Not yet recruiting
NCT02875548 2025-11-04
TRuST
Ipsen
Phase 1/2 Completed
NCT05372354 2025-09-05
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn